Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Brain Pathol. 2015 Apr 20;25(4):391–400. doi: 10.1111/bpa.12161

Figure 3.

Figure 3

Loss of Sparc suppresses the in vivo tumor growth and proliferation of p53-null astrocytes. Intracranial xenografts of p53-null/Sparc-wt and p53-null/Sparc-null astrocytes were assessed at 7 days post-implantation. Brains were harvested, formalin-fixed, and paraffin-embedded. Tumor xenograft sections were H&E stained and immunohistochemically stained for mouse SPARC and the proliferation marker Ki-67. Magnifications as indicated. Representative images shown for 2 Sparc-wt and 2 Sparc-null animals out of n = 12 animals/group at day 7.